12.35
+3.35%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Acepodia
Its shares trade on Taipei Exchange under the ticker 6976.TWO. It has been listed since 8 August 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 185,000 and a net loss of TWD 754.4m. At that date it held total assets of TWD 5.83bn and shareholders' equity of TWD 5.42bn.
Acepodia Inc is a TW-based company operating in Biotechnology industry. The company is headquartered in Taipei, New Taipei. The company went IPO on 2023-08-08. Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The firm uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Aug 2023
- Website
- acepodia.com ↗
Leadership
Pay as last reported
- Dr. Sonny HsiaoChairman of the Board, Chief Executive Officer, General Manager, since 2024
- Dr. Mark GilbertSenior Vice President - R&D
- Dr. Joseph McCrackenSenior Vice President - Business Development
- Yajun WangChief Technology Officer, Chief Quality Officer, since 2024
- Mr. Guangyi OuyangHead of Finance
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Acepodia Inc's Gamma delta 2T cell platform includes ACE1831 for lymphoma treatment targeting CD20.
- ACE2016 targets EGFR+ solid tumors like lung cancer using antibody linked technology.
- ACE1708 targets PDL1 for solid tumor treatment with antibody linked technology.
Weaknesses
- Acepodia Inc's ACE1702 targets HER2+ solid tumors such as breast cancer with off-the-shelf natural killer cell technology.
- The company's ACE2016 focuses on EGFR+ solid tumors including lung cancer treatment.
- ACE1708 targets PDL1 for solid tumor treatment using antibody linked technology.
Opportunities
- Acepodia Inc's ACE1831 is in clinical trials for lymphoma treatment targeting CD20.
- ACE2016 is being developed for EGFR+ solid tumors like lung cancer.
- ACE1708 is in development for PDL1 solid tumor treatment.
Threats
- Acepodia Inc's ACE1702 is in clinical trials for HER2+ breast cancer treatment.
- The company's ACE2016 faces competition in EGFR+ solid tumor markets.
- ACE1708 encounters challenges in PDL1 solid tumor treatment markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.